May 10, 2024, 14:58 | Blog

Lauren Brown: Another insightful article out of the AURORA collaboration

Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical…

May 9, 2024, 06:46 | Societies

12 Posts Not To Miss From The 3rd International Summit on Lung Cancer!

The 3rd International Summit on Lung Cancer (RomeLung24), organized by the International Association for the…

May 8, 2024, 00:58 | Blog

Stephen V Liu: Dr. Passiglia Fra at Rome Lung 24 illustrates the limited role of immunotherapy in driver positive NSCLC

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University at Lombardi…

May 8, 2024, 00:50 | Blog

Stephen V Liu: Dr. Giulia Pasello at Rome Lung 24 discusses duration of immunotherapy for NSCLC

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University at Lombardi…

May 6, 2024, 19:10 | Blog

Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations

Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X: "Metastatic NSCLC without oncogenic…

May 6, 2024, 12:58 | Blog

Iván R. González: The NEOpredict-Lung study represents an importantevolution in the treatment of resectable NSCLC

Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post…

May 3, 2024, 15:47 | Blog

Percy Lee: ACCC webinar on advances in management of early stage NSCLC

Percy Lee, Professor and Section Chief of the Thoracic Radiation Oncology at The University of Texas…

May 3, 2024, 04:28 | Blog

Erman Akkus: Roundup of the last year-Practice changing trials in NSCLC

Erman Akkus, Medicine Oncology and Internal Medicine Specialist at Ankara University, shared on X/Twitter: "Roundup…

May 2, 2024, 15:25 | Blog

Tanja Obradovic: Interesting updates will be coming on ASCO 2024

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…

May 2, 2024, 14:30 | Societies

Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC - ASCO

American Society of Clinical Oncology (ASCO) shared on X: “Breaking news from the ASCO Plenary Series:…

May 2, 2024, 14:14 | Blog

Stephen V Liu discusses KRAS mutant NSCLC with Veluswamy and Mariana Brandao - IASLC

International Association for the Study of Lung Cancer (IASLC) shared on X: “KRAS mutations are…

May 1, 2024, 09:08 | Insight

Piotr Wysocki: Adjuvant immunotherapy in NSCLC patients who underwent radical resection preceded by immunotherapy

Piotr Wysocki recently shared on LinkedIn: "Zhou Y et al. have conducted an indirect meta-analysis…

Apr 30, 2024, 07:31 | Insight

Top 5 posts of the week by Cancer Network

Cancer Network shared on their X/Twitter page: "View our top 5 posts of the week:…

Apr 30, 2024, 06:04 | Insight

Martin Reck: Update on advanced non oncogenic NSCLC in ASCO Educational Book

Martin Reck, Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, shared…

Apr 29, 2024, 15:02 | Blog

Patrick Forde: 3 lung cancer plenaries at ASCO24!

Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at…

Apr 29, 2024, 05:46 | Blog

Nagashree Seetharamu: Navigating Treatment Beyond 3 Years of Survival in Metastatic EGFR+ NSCLC

Nagashree Seetharamu, Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at…

Apr 29, 2024, 00:06 | Blog

Hear from an expert panel about recent advances in NSCLC - ACCC

Percy Lee, Professor and Vice-Chair of Clinical Research at City of Hope, shared a post…

Apr 28, 2024, 16:38 | Blog

Hidehito Horinouchi: Abstract Titles Clinical Science Symposium: Targeting KRAS in NSCLC

Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital, shared a…

Apr 28, 2024, 12:40 | Blog

Cancer at Cedars-Sinai is now recruiting patients with advanced NSCLC in a clinical trial

Cancer at Cedars-Sinai posted on X/Twitter: "If you have advanced non-small cell lung cancer, you…

Apr 28, 2024, 11:04 | Blog

Ana I. Velázquez Mañana: ASCO24 abstract titles are out! Exciting Plenary Session, specially for LCSM community

Ana I. Velázquez Mañana shared on X/Twitter: “ASCO24 abstract titles are out! Exciting Plenary Session, specially…

Apr 27, 2024, 08:27 | Societies

American Radium Society Appropriate Use Criteria Thoracic Committee provided guidance on the management of unresectable locally advanced NSCLC - MSK Radiation Oncology

Memorial Sloan Kettering Radiation Oncology shared on X: “Evidence-based guidance on the management of unresectable…

Apr 26, 2024, 10:07 | Drugs

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…

Apr 26, 2024, 10:00 | Insight

Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…

Apr 26, 2024, 09:26 | Insight

Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: ''First-line treatment…

Apr 25, 2024, 19:48 | Insight

New Paper Alert! The INNOVATED Cohort: The Role of Immune Checkpoint Blockers in Solid Organ Transplant Recipients with Cancer

The INNOVATED Cohort: The Role of Immune Checkpoint Blockers in Solid Organ Transplant Recipients with…

Apr 23, 2024, 18:57 | Insight

New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature

Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…

Apr 23, 2024, 10:44 | Blog

Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial

Ben Solomon, Lung Cancer Medical Oncologist at Peter MacCallum Cancer Centre, shared a post by…

Apr 22, 2024, 19:23 | Insight

New Paper Alert! A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners Foundation

A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners…

Apr 22, 2024, 18:48 | Insight

Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression

Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…

Apr 22, 2024, 05:14 | Insight

Chul Kim: In-depth review of BRAF mutant NSCLC by Dr. Marcelo Negrao at Texas Lung 24 Conference

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X: "In-depth review…

Apr 21, 2024, 18:13 | Blog

Antonio Passaro: An intense yet incredibly rewarding day in Oporto

Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared a…

Apr 20, 2024, 06:18 | Insight

New Paper Alert! Addressing BRAF V600E in Metastatic Non-Small Cell Lung Cancer

Addressing BRAF V600E in Metastatic Non-Small Cell Lung Cancer Authors: David Planchard, Rachel E. Sanborn,…

Apr 20, 2024, 06:08 | Insight

David Planchard: Some advances for our BRAF V600E NSCLC patients…Review to read at npj Journals

David Planchard, Professor at the University of Paris-Saclay, posted on X/Twitter: "Some advances for our BRAF…

Apr 19, 2024, 15:52 | Drugs

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial

FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…

Apr 17, 2024, 17:25 | Insight

Susanna Greer: A 'not-so-small' discovery for non-small cell lung cancer

Susanna Greer, Chief Scientific Officer at the V Foundation for Cancer Research, published the following…

Apr 16, 2024, 01:50 | Blog

Jarushka Naidoo: Starting day 2 with Patrick Forde on periop chemo-IO in nsclc

Jarushka Naidoo shared on X/Twitter: "AILCC24 Starting day 2 with Patrick Forde on periop chemoIO in nsclc.…

Apr 15, 2024, 13:28 | Insight

Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study

Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn: ''I am thrilled…

Apr 15, 2024, 04:04 | Blog

Amalya Sargsyan: Proud to see IMMONC spotlighted in ASCO's latest policy statement on global equity in clinical trials

Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, posted on LinkedIn: "Extremely proud to…

Apr 15, 2024, 01:09 | Blog

Antonio Passaro: Our editorial on the groundbreaking ALINA trial

Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on X/Twitter: "Just published in…

Apr 14, 2024, 07:35 | Drugs

Charles Swanton: What is the role of the TME in lung cancer evolution?

Charles Swanton, Professor at University College London Cancer Institute, shared on X/Twitter: "What is the role…

Apr 14, 2024, 02:26 | Insight

Vivek Subbiah: A pan-cancer analysis of the microbiome in metastatic cancer

Quoting Vivek Subbiah on X/Twitter: "A pan-cancer analysis of the microbiome in metastatic cancer: Cell.…

Apr 13, 2024, 08:37 | Insight

New Paper Alert! How concurrent Medication Impacts The Outcomes Of Patients Treated with Immune Checkpoint Inhibitors

How concurrent Medication Impacts The Outcomes Of Patients Treated with Immune Checkpoint Inhibitors Published in…

Apr 13, 2024, 08:19 | Blog

Excited to share our paper on Precision Immuno-Oncology in NSCLC through Gender Equity Lenses - Florez Lab

Florez Lab shared on X/Twitter: "New Florez Lab Publication Alert!! Excited to share our paper on Precision…

Apr 12, 2024, 11:46 | Drugs

Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM

Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…

Apr 12, 2024, 10:05 | Drugs

Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure

Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…

Apr 11, 2024, 17:15 | Blog

Oyepeju Abioye: 'Precision Immuno-Oncology in NSCLC through Gender Equity Lenses', published in MDPI

Oyepeju Abioye, Oncology Clinical Research Assistant at Florez Laboratory of Dana-Farber Cancer Institute, shared on X:…

Apr 9, 2024, 09:03 | Insight

Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC

Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…

Apr 8, 2024, 22:24 | Insight

NSCLC's Immune Landscape: A Comprehensive Study of the Tumor Microenvironment

A recent study, “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical…

Apr 8, 2024, 15:24 | Insight

Amalya Sargsyan: Fantastic paper out in AACR Journals on the role of TME in NSCLC

Amalya Sargsyan, Medical Oncologist at Yeolyan Oncology and Hematology Center, shared on LinkedIn: "Is targeting…

Apr 8, 2024, 14:35 | Insight

Biagio Ricciuti: Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, posted on X: "Our collaborative effort to…

Apr 7, 2024, 23:28 | Insight

Biagio Ricciuti: MET kinase domain mutations as novel & targetable alterations in NSCLC and other cancer types

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X: "Our collaborative effort to…

Apr 6, 2024, 14:49 | Insight

Chul Kim: Check out our article featured in ASCO Daily News

Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, recently shared…

Apr 5, 2024, 18:10 | Insight

Chul Kim: Check out our podcast on the importance of biomarker testing in the treatment of advanced NSCLC

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X: "Check out…

Apr 5, 2024, 08:16 | Insight

Oscar Arrieta: Our study shows the impact on overall survival of integrating palliative care early in NSCLC patients

Oscar Arrieta, Head of the Thoracic Oncology Unit at National institute of Oncology in Mexico,…

Apr 4, 2024, 13:34 | Drugs

Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…

Apr 3, 2024, 06:05 | Blog

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn: “Most viewed in the last 7 days from…

Apr 1, 2024, 12:55 | Insight

Nicholas Sarlis: Dr Luis Raez succinctly describes recently reported results from key clinical trials in NSCLC patients

Nicholas Sarlis, Chief Medical Officer at CLEARA Biotech BV, shared a post on LinkedIn: "Dr.…

Mar 31, 2024, 23:12 | Insight

Stephen V Liu: Results from phase III CONTACT-01 trial Journal of Clinical Oncology

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…

Mar 31, 2024, 08:18 | Drugs

Jeffrey Martin: Bispecific antibodies - what are they and who's making them?

Jeffrey Martin, Founder of Oncoleader, recently shared on LinkedIn: "Bispecific antibodies: what are they and…

Mar 29, 2024, 18:40 | Insight

Jarushka Naidoo: Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+ NSCLC meets primary PFS endpoint

Jarushka Naidoo shared on X/Twitter: "Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+…

Mar 25, 2024, 15:21 | Insight

Gerry Hanna: Breaking from ELCC - PACIFIC-2 is negative

Gerry Hanna, Chair of the Division of Cancer and Specialist Medicine at Belfast Health and…

Mar 25, 2024, 15:14 | Societies

Giannis Mountzios: ELCC24, Daniel Tan performs a deep dive in Bi-specific Abs/BiteS/T-cell engagers in NSCLC

Giannis Mountzios, Consultant Medical Oncologist at the Department of Medical Oncology in the Air Force…

Mar 25, 2024, 15:09 | Insight

Jarushka Naidoo: Surgical outcomes of RATIONALE-315 (Neoadjuvant Tis + chemo in resectable NSCLC)

Jarushka Naidoo recently posted on X: "Surgical outcomes of RATIONALE-315 (Neoadjuvant Tis+chemo in resectable NSCLC): -…

Mar 25, 2024, 06:01 | Insight

Vivek Subbiah: For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations

Vivek Subbiah recently posted on X: "Just published in time for the ELCC24: The Impact of…

Mar 18, 2024, 19:25 | Blog

Arsela Prelaj: I defended my PhD thesis with Laude in bioengineering and AI at polimi on multimodal data to predict IO in NSCLC

Arsela Prelaj, Medical Oncologist at the Thoracic Unit of National Cancer Institute of Milan in…

Mar 16, 2024, 10:29 | Dialogues

OncoDaily Dialogues #6 – Navneet Singh / Hosted by Roupen Odabashian

In our ongoing series called "OncoDaily Dialogues," we consistently feature prominent individuals in the field…

Mar 12, 2024, 20:33 | Insight

Jarushka Naidoo: Is chemo-ICI or ICI preferable, in patients older than 75yrs with advanced NSCLC?

Jarushka Naidoo shared on X/Twitter: "Is chemo-ICI or ICI preferable, in pts >75yrs with advanced…

Mar 11, 2024, 18:00 | Societies

Florez Lab: A fantastic discussion on Nivolumab and Non-Small Cell Lung Cancer

Florez Lab posted on X/Twitter: "What podcast should you listen to today? In this episode…

Mar 11, 2024, 03:11 | Blog

Herbert Loong: A privilege to participate and co-chair an informative event held at Amgen Oncology in Kuala Lumpur

Herbert Loong, Clinical Associate Professor at the Chinese University of Hong Kong, shared on X/Twitter:…

Mar 8, 2024, 20:11 | Blog

Ramy Sedhom: The new ASCO guideline represents amazing advances for pts with NSCLC and driver alterations

Ramy Sedhom, Clinical Director of Palliative Care at Penn Medicine Princeton Health, shared a post on…

Mar 5, 2024, 00:54 | Blog

Stephen V. Liu: Report Clinical Lung Cancer shows improving lung cancer survival in the Veterans Administration

Stephen V. Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…

Mar 1, 2024, 03:00 | Blog

A survey of U.S. oncologists on the use of innovative treatments - Cancer Research Institute

Cancer Research Institute shared a post on LinkedIn: "Advancements in the research and treatment of advanced…

Feb 28, 2024, 18:42 | Drugs

Amalya Sargsyan: Excitement around osimertinib in the NSCLC community

Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn: "Huge…

Feb 24, 2024, 16:34 | Blog

Chul Kim: What are other relevant targets for ADC therapy in NSCLC?

Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: "What are…

Feb 11, 2024, 15:07 | Blog

Drew Moghanaki: This year's The Radio-surgery Society Scientific Meeting, the agenda assumes "Some SBRT" is better than "No SBRT"

Drew Moghanaki, Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology, shared a post…

Feb 10, 2024, 15:34 | Insight

Alessandro Russo: Our editorial on the potential role of ctDNA in resectable NSCLC undergoing neo-adj chemo

Alessandro Russo, Medical Oncologist at A.O. Papardo, Messina, recently shared the following insight on X/Twitter:…

Feb 9, 2024, 17:42 | Insight

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Centre, shared an X post by…

Feb 7, 2024, 12:46 | Blog

Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC

Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…

Feb 5, 2024, 11:27 | Insight

Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…

Feb 1, 2024, 17:31 | Insight

Paolo Tarantino: Any agnostic approval should not stop efforts in biomarker discovery for ADCs

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Of…

Jan 24, 2024, 22:30 | Insight

Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC

Raffaele Colombo, Principal Scientist at Zymeworks, shared on X: "Evoke-01 study of sacituzumab govitecan (SG)…

Jan 22, 2024, 13:58 | Insight

Percy Lee: HyCRT-SABR for unresectable locally advanced NSCLC

Percy Lee, Professor and Vice-Chair of Clinical Research at City of Hope, shared on X/Twitter:…

Jan 18, 2024, 15:55 | Blog

Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn: “Now out in the…

Jan 13, 2024, 10:04 | Blog

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by…

Jan 8, 2024, 14:21 | Blog

Drew Moghanaki shared a study from Duke University on Stage I NSCLC

Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared a post on…

Dec 21, 2023, 09:57 | Insight

Chiaojung Jillian Tsai: CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer

Chiaojung Jillian Tsai, Lead of Palliative Radiotherapy and Oligometastasis Program (PROP) at Princess Margaret Cancer…

Dec 13, 2023, 17:07 | Insight

Drew Moghanaki: This insightful study by Michael Farris reminds us that communication gaps affect patient care

Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared on X/Twitter: "I…

Dec 5, 2023, 19:09 | Blog

Narjust Florez: Ready for a Pregnancy and Lung Cancer Tweetorial?

Narjust Florez shared a post on her X/Twitter page: "Ready for a Pregnancy and Lung…

Dec 5, 2023, 18:49 | Blog

Katsuaki Maehara: Stage Ⅳ EGFRm NSCLC - Sequential Treatment Options

Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on Twitter: "Stage Ⅳ…

Dec 2, 2023, 15:23 | Blog

Yüksel Ürün: The ctDNA clearance during definitive SOC therapy is associated with improved outcome

Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter: "A study shows combining circulating…

Nov 28, 2023, 16:43 | Drugs

Vivek Subbiah: Pleased to share our review on RET inhibitors

Vivek Subbiah shared on LinkedIn: "Pleased to share our review on RET inhibitors and RET inhibitor…

Nov 27, 2023, 17:17 | Insight

Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020

Vivek Subbiah shared on LinkedIn: “Pleased to share our paper in American Cancer Society journal…

Nov 18, 2023, 17:04 | Opinion

Aakash Desai: Tune in to our podcast episode for an in-depth dive into HER3 therapy's development and clinical possibilities

Aakash Desai, Assistant Professor at the O’Neal Comprehensive Cancer Center at UAB Medicine, posted on X/Twitter:…

Nov 12, 2023, 17:56 | Drugs

David Planchard: Thank you to the patients who actively participated in this research

David Planchard, Professor at the University Paris Saclay, posted on X/Twitter. "Proud to lead this…

Nov 1, 2023, 09:45 | Insight

Alessandro Inno: A case of a very elderly patient with MET-exon 14 mutant NSCLC with meaningful and durable benefit from first-line tepotinib, with an acceptable safety profile

Oct 29, 2023, 03:16 | Drugs

Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…

Oct 27, 2023, 04:23 | Insight

The first randomised trial of a targeted agent versus immunotherapy plus chemotherapy in a biomarker-selected patient population - CUHK Medicine

CUHK Medicine shared on LinkedIn: " More than doubled lung cancer patients’ progression-free survival Lung…

Oct 23, 2023, 13:26 | Insight

Marcelo Corassa: Great presentation by the amazing Jarushka Naidoo on the promises and pitfalls of neoadjuvant therapy for NSCLC

Marcelo Corassa, Medical oncologist and Clinical Researcher at Beneficência Portuguesa de São Paulo, shared on…

Oct 22, 2023, 17:22 | Blog

Giulio Draetta: Tremendously proud of Tina Cascone for her presentation at the 2023 ESMO meeting presidential session

Giulio Draetta, Chief Scientific Officer at The University of Texas M.D. Anderson Cancer Center, shared…

Oct 21, 2023, 19:37 | Blog

Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.

Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and…